每日自适应1.5 T MR-Linac图像引导再照射治疗前列腺癌:国际回顾性经验
这项国际回顾性研究评估了75例放疗后局部复发前列腺癌患者接受1.5 T MR-Linac每日自适应立体定向体部放疗再照射的安全性和疗效。中位随访11.9个月,12个月无失败生存率96.6%,24个月76.5%;胃肠道不良反应轻微,但泌尿生殖系统3级不良反应在12个月时升至12.5%。
要点
- 再照射采用每日自适应MR-Linac,最常用方案为30 Gy分5次,46.7%行局灶治疗。
- 12个月无失败生存率96.6%,24个月76.5%,失败均发生在24个月内且局限于前列腺/瘤床或精囊。
- 12个月时泌尿生殖系统3级不良反应为12.5%,无4级及以上事件;胃肠道无2级及以上事件。
核心结论
- 对于局部复发前列腺癌,1.5 T MR-Linac每日自适应再照射可行,胃肠道毒性可接受,但短期至中期泌尿生殖系统毒性不可忽视。
研究设计与样本
- 国际多中心回顾性研究,纳入4个中心共75例生化或组织学确认的放疗后局部复发前列腺癌患者,接受1.5 T MR-Linac自适应SBRT再照射。
主要发现
- 从初始根治治疗到复发的中位间隔为79.0个月(IQR 56.2-126.5),再照射时中位年龄73.3岁(IQR 68.5-77.7)。
- 再照射后中位随访11.9个月(IQR 3.5-21.1),12个月无失败生存率96.6%(95% CI 92.0-100.0),24个月76.5%(95% CI 62.8-93.2)。
- 3个月时泌尿生殖系统不良反应Grade 0-1占85.3%(64/75),Grade 2占13.3%(10/75),Grade 3占1.3%(1/75);12个月时Grade 3升至12.5%(6/48),无Grade ≥4事件。
- 胃肠道不良反应轻微,任何时间点均未观察到Grade 2或以上事件。
关键数值与推荐
- 再照射最常用方案为30 Gy分5次,46.7%接受局灶(仅GTV)治疗,53.3%接受全腺体治疗。
临床怎么用
- 对于放疗后局部复发前列腺癌,可考虑采用每日自适应MR-Linac行SBRT再照射,但需重点监测泌尿生殖系统毒性。
局限性
- 回顾性研究设计,样本量75例,中位随访仅11.9个月,12个月时泌尿生殖系统毒性评估仅48例可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Local recurrence in prostate cancer (PCa) after radical radiotherapy has become increasingly prevalent in the era of next-generation imaging. Meta-analyses suggest a favourable adverse event (AE) profile for stereotactic body radiotherapy (SBRT). This study aimed to evaluate the safety and efficacy of high-precision daily adaptive 1.5 T MR-Linac re-irradiation (re-EBRT). METHODS: This international retrospective study evaluated outcomes in patients with locally radio-recurrent PCa treated with adaptive SBRT re-EBRT on a 1.5 T MR-Linac platform. Eligible patients had biochemically or histologically confirmed radiological local recurrence within the previously irradiated prostate or prostate bed. Clinical characteristics, treatment, AE, and follow-up data were summarised using descriptive statistics and Kaplan-Meier methods. RESULTS: Seventy five patients were included across four centres. The median interval from primary radical therapy to recurrence was 79.0 months (IQR 56.2-126.5). Median PSA at initial presentation was 8.1 ng/mL (IQR 6.0-11.8), with a median PSA at recurrence of 2.2 ng/mL (IQR 1.0-3.6). Median age at re-EBRT was 73.3 years (IQR 68.5-77.7). MRI-guided adaptive radiotherapy (MRIgART) was delivered with hypofractionated regimens, most commonly 30 Gy in 5 fractions, with 46.7% receiving focal (GTV-only) and 53.3% whole-gland treatment. At 3 months, genitourinary AE were Grade 0-1 in 85.3% (64/75) of patients, Grade 2 in 13.3% (10/75) and Grade 3 AE in 1.3% (1/75). By 12 months, Grade 3 AE had risen to 12.5% (6/48), with no Grade ≥ 4 events. Gastrointestinal AE were mild, with no Grade 2 or higher events observed at any timepoint. Median post-re-EBRT follow-up was 11.9 months (IQR 3.5-21.1 months). Failure-free survival was 96.6% (95% CI 92.0-100.0) at 12 months and 76.5% (95% CI 62.8-93.2) at 24 months. The failures observed occurred within 24 months and were confined to intraprostatic/prostate bed or seminal vesicle sites. CONCLUSIONS: MRIgART re-EBRT is feasible for locally recurrent PCa, with acceptable gastrointestinal but non-negligible short to medium-term genitourinary toxicity.Data sharing statement: Research data are not available at this time. All centres subscribe to the MOMENTUM registry, from which data access requests can be made by participating centres.
引用
- Cooper S, Brennan VS, Alongi F, et al. Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience. Clin Transl Radiat Oncol. 2026. PMID: 42787873. doi:10.1016/j.ctro.2026.101287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。